Created in 2015 (United States), RAPIVAB own 4 sister brands and 2214 competing brands. RAPIVAB is owned by BioCryst Pharmaceuticals, listed on the stock exchange of New York RAPIVAB belongs to the Biotechnology business sector.
Investment simulator :
Portfolio valuation
BioCryst Pharmaceuticals
(RAPIVAB)
over 5 years*
USD 3.26